<DOC>
	<DOCNO>NCT00234923</DOCNO>
	<brief_summary>The purpose pilot study obtain preliminary assessment antiviral activity tolerability Kaletra single agent therapy initial treatment HIV infection , relative Kaletra three drug standard care reference arm</brief_summary>
	<brief_title>Efficacy Safety Kaletra Monotheraphy Compared Kaletra Based Triple Therapy Treat HIV Antiretroviral Naїve Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Antiretroviral naïve HIV RNA &lt; 100,000 copies/mL CD4 cell count &gt; 100 cells/mL screen Karnofsky Score &gt; 70 If female , nonpregnant breastfeed No AIDS opportunistic infection within 30 day screen Subject HIV primoinfection status Recent history drug and/or alcohol abuse History psychiatric illness If presence follow mutation : protease : one among 32,47,48,50,82,84,90 OR 3 mutation point LPV mutation score:10,20,24,46,53,54,63,71 reverse transcriptase : 215 184 . If abnormal laboratory result : Hb &lt; 8 g/dl Absolute neutrophil count &lt; 750 cells/µl Platelet count &lt; 50 000/ml</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>HIV Infection</keyword>
	<keyword>Kaletra</keyword>
	<keyword>Lopinavir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>